veliparib (ABT-888) / AbbVie  >>  Phase 2
Welcome,         Profile    Billing    Logout  

46 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
veliparib (ABT-888) / AbbVie
M10-897, ACTRN12612001245886: A Clinical Study Conducted in Multiple Centers Comparing Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Subjects With Brain Metastases From Non Small Cell Lung Cancer (NSCLC)

Recruiting
2
300
 
AbbVie Pty Ltd, AbbVie Pty Ltd
Brain Metastases from Non-Small Cell Lung Cancer
 
 
PMID31976786: Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation

Completed
2
50
New York
cisplatin - Generic mfg., gemcitabine - Generic mfg., veliparib (ABT-888) - AbbVie
Memorial Sloan Kettering Cancer Center
Pancreatic ductal adenocarcinomas (PDACs)
 
 
NCT01193140: To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors

Completed
2
24
US
veliparib, ABT-888, Temozolomide, Temodar
Abbott
Solid Tumor Cancers
11/11
11/11
NCT01051596: A Study of ABT-888 in Combination With Temozolomide for Colorectal Cancer

Completed
2
75
US
Temozolomide, Temodar, ABT-888, Veliparib
Georgetown University, Abbott
Colorectal Cancer
06/13
12/13
NCT01113957 / 2009-015082-31: A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer

Completed
2
168
US, Canada, Europe, RoW
ABT-888, ABT-888, veliparib, pegylated liposomal doxorubicin, doxil/caelyx, temozolomide, temozolomide, temodar/temodal
AbbVie (prior sponsor, Abbott)
Ovarian Cancer
06/13
06/13
NCT01560104 / 2011-003427-36: A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer

Checkmark Veliparib/carboplatin/paclitaxel vs. carboplatin/paclitaxel in previously untreated NSCLC
Nov 2016 - Nov 2016: Veliparib/carboplatin/paclitaxel vs. carboplatin/paclitaxel in previously untreated NSCLC
Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Checkmark ELCC 2015
More
Completed
2
160
US, Canada, Europe, RoW
Veliparib, ABT-888, Carboplatin, paclitaxel, placebo
AbbVie (prior sponsor, Abbott)
Non-Small -Cell Lung Cancer
09/14
09/14
NCT01205828: ABT-888 and Temozolomide for Liver Cancer

Checkmark ASCO-GI 2014
Jan 2014 - Jan 2014: ASCO-GI 2014
Terminated
2
16
US
Temozolomide, Temodar, ABT-888, Veliparib
Georgetown University, Abbott
Hepatocellular Carcinoma
10/14
10/14
NCT01306032: Phase II ABT-888 With Cyclophosphamide

Checkmark P2 data-ASCO
Jun 2012 - Jun 2012: P2 data-ASCO
Completed
2
124
US, Canada
ABT-888, Veliparib, Cyclophosphamide, Cytoxan
National Cancer Institute (NCI)
Ovarian Cancer, Primary Peritoneal Cancer, Serous Carcinoma Cancer, Triple-Negative Breast Cancer, Fallopian Tube Cancer
12/14
12/16
NCT01657799 / 2011-003618-18: Comparison of Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Adults With Brain Metastases From Non-Small Cell Lung Cancer

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Completed
2
307
NA
Veliparib, ABT-888, Placebo, Whole brain radiation therapy
AbbVie (prior sponsor, Abbott)
Brain Metastases From Non-small Cell Lung Cancer
01/15
01/15
NCT01818063: Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer

Completed
2
9
US
Paclitaxel, Taxol, Abraxane, Carboplatin, cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), Paraplatin, Paraplatin-AQ, Doxorubicin, Adriamycin, hydroxydaunorubicin, Adriamycin PFS, Adriamycin RDF, Rubex, Doxil, Cyclophosphamide, Endoxan, Cytoxan, Neosar, Procytox, Revimmune, cytophosphane, Lyophilizedcytoxan, Veliparib, ABT-888
Sidney Kimmel Cancer Center at Thomas Jefferson University, Susan G. Komen Breast Cancer Foundation
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-negative Breast Cancer
03/15
12/18
2014-003785-24: Treatment of pancreatic adenocarcinoma with the combinationof carboplatin and velparib Hasnyálmirigy adenocarcinoma kezelése karboplatin és veliparib kombinációjával

Completed
2
1
Europe
Veliparib 40 mg, ABT-888, Capsule, Concentrate for solution for infusion
Uzsoki Utcai Kórház, AbbVie Deutschland GmbH & Co. KG
pancreatic adenocarcinoma, pancreas tumor, Diseases [C] - Cancer [C04]
 
 
NCT00804908 / 2008-004941-27: A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma

Checkmark Veliparib/temozolomide vs. TMZ in metastatic melanoma
Jul 2015 - Jul 2015: Veliparib/temozolomide vs. TMZ in metastatic melanoma
Checkmark Data
Oct 2011 - Oct 2011: Data
Checkmark Data
More
Completed
2
346
NA
temozolomide, Temodar, Temodal, ABT-888, veliparib, Placebo
AbbVie (prior sponsor, Abbott)
Melanoma, Metastatic Melanoma, Skin Cancer
01/16
01/16
NCT01266447: Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer

Completed
2
27
US
Filgrastim, Filgrastim XM02, G-CSF, Neupogen, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, rG-CSF, Tbo-filgrastim, Tevagrastim, Laboratory Biomarker Analysis, Pegfilgrastim, Filgrastim SD-01, filgrastim-SD/01, HSP-130, Neulasta, Pegfilgrastim Biosimilar HSP-130, SD-01, SD-01 sustained duration G-CSF, Topotecan Hydrochloride, Hycamptamine, Hycamtin, SKF S-104864-A, Topotecan HCl, topotecan hydrochloride (oral), Veliparib, ABT-888, PARP-1 inhibitor ABT-888
National Cancer Institute (NCI), NRG Oncology
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma, Stage III Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer
01/16
01/16
NCT01642251: Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Completed
2
156
US
Cisplatin, Cisdiaminedichloroplatinum, Cis -diaminedichloroplatinum (II), diaminedichloroplatinum, Platinol -AQ, Cis-platinum, P latinol, platinum, DDP, CDDP, DACP, NSC 119875, Etoposide, Epipodophyllotoxin, EPEG, Vepesid, VP 16-213, VP-16, Veliparib, ABT-888, PARP-1 inhibitor ABT-888, A-861695.0, Placebo, placebo therapy
National Cancer Institute (NCI)
Extensive Stage Small Cell Lung Carcinoma, Large Cell Lung Carcinoma, Neuroendocrine Carcinoma, Small Cell Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
12/16
07/18
NCT01638546: Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

Checkmark In combination with temozolomide in patients with r/r SCLC
Jul 2018 - Jul 2018: In combination with temozolomide in patients with r/r SCLC
Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Active, not recruiting
2
97
US
Laboratory Biomarker Analysis, Placebo Administration, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ, Veliparib, ABT 888, ABT-888, ABT888, PARP-1 inhibitor ABT-888
National Cancer Institute (NCI)
Recurrent Lung Small Cell Carcinoma
01/17
03/26
NCT02305758 / 2014-002866-65: Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer

Completed
2
130
NA
Veliparib, ABT-888, Placebo, Modified FOLFIRI, FOLFIRI, Bevacizumab, Avastin, Fluorouracil infusion, 5-FU
AbbVie
Untreated Metastatic Colorectal Cancer
09/17
09/17
NCT01540565: Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Checkmark In recurrent BRCA-mutant ovarian cancer
Jun 2013 - Jun 2013: In recurrent BRCA-mutant ovarian cancer
Completed
2
52
US
Laboratory Biomarker Analysis, Veliparib, ABT-888, PARP-1 inhibitor ABT-888
National Cancer Institute (NCI), NRG Oncology
BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ovarian Epithelial Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
01/18
01/18
VERTU, ACTRN12615000407594: A Randomised Phase II study of Veliparib, Radiotherapy and Temozolomide in patients with unmethylated O (6)-methylguanine-DNA methyltransferase (MGMT) Glioblastoma (brain cancer) ( study)

Active, not recruiting
2
120
 
The University of Sydney, Cure Brain Cancer Foundation, Cancer Council New South Wales
Glioblastoma Multiforme
 
 
NCT01506609 / 2011-002913-12: Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer

Checkmark Germline BRCA1/2 mutation mBC
Oct 2017 - Oct 2017: Germline BRCA1/2 mutation mBC
Completed
2
294
Europe, Canada, US, RoW
Placebo, Veliparib, ABT-888, Carboplatin, Temozolomide, Temodal, Paclitaxel, Taxol
AbbVie
Metastatic Breast Cancer
12/18
09/20
NCT03032614: Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients

Withdrawn
2
0
NA
Carboplatin, Paraplatin, Eribulin, Halaven, E7389, Veliparib, ABT-888
The University of Texas Health Science Center at San Antonio
Breast Cancer Stage IV, Ovarian Cancer, BRCA1 Mutation, BRCA2 Mutation
03/19
04/20
S1513, NCT02890355: FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

Active, not recruiting
2
123
US
Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Irinotecan Hydrochloride, Campto, Camptosar, Camptothecin 11, Camptothecin-11, CPT 11, CPT-11, CPT11, Irinomedac, Irinotecan Hydrochloride Trihydrate, Irinotecan Monohydrochloride Trihydrate, U 101440E, U-101440E, U101440E, Laboratory Biomarker Analysis, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Veliparib, ABT 888, ABT-888, ABT888, PARP-1 inhibitor ABT-888
National Cancer Institute (NCI)
Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7
05/19
03/26
NCT01576172: Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Completed
2
159
US
Abiraterone Acetate, CB7630, Yonsa, Zytiga, Laboratory Biomarker Analysis, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Veliparib, ABT-888, PARP-1 inhibitor ABT-888
National Cancer Institute (NCI)
Castration-Resistant Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7
10/19
04/20
NRG-GI002, NCT02921256: Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer

Checkmark Data from P2 trial with combination chemo and radiation therapy in locally advanced rectal cancer at ASCO-GI 2023
Jan 2023 - Jan 2023: Data from P2 trial with combination chemo and radiation therapy in locally advanced rectal cancer at ASCO-GI 2023
Completed
2
363
US
Capecitabine, Ro 09-1978/000, Xeloda, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Intensity-Modulated Radiation Therapy, IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Leucovorin, Folinic acid, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Pembrolizumab, BCD-201, Keytruda, Lambrolizumab, MK-3475, Pembrolizumab Biosimilar BCD-201, SCH 900475, Veliparib, ABT-888, PARP-1 inhibitor ABT-888
National Cancer Institute (NCI), NRG Oncology
Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v7, Stage III Rectal Cancer AJCC v7
04/20
09/23
REPAIR, NCT03044795: Response to PARP Inhibitor Predicted by the RAD51 Assay

Withdrawn
2
0
NA
Veliparib
University Medical Center Groningen, AbbVie, Dutch Cancer Society
Cancer
11/20
11/20
GCTSK004, NCT02860819 / 2016-000171-24: Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer

Completed
2
15
Europe
Veliparib, ABT-888, Gemcitabine, Carboplatin
National Cancer Institute, Slovakia
Testicular Cancer
11/20
02/21
NCT01009788: ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer

Checkmark P2 data- SABCS
Dec 2011 - Dec 2011: P2 data- SABCS
Completed
2
63
US
ABT-888, veliparib, temozolomide, TMZ
Steven J Isakoff, MD, PhD, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Abbott
Breast Cancer, Metastatic Breast Cancer, BRCA1 Gene Mutation, brca2 Gene Mutation
09/12
09/15
NCT01827384: MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations

Completed
2
208
US
Adavosertib, AZD-1775, AZD1775, MK-1775, MK1775, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Everolimus, 42-O-(2-Hydroxy)ethyl Rapamycin, Afinitor, Certican, RAD 001, RAD001, Votubia, Zortress, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac, TMZ, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Veliparib, ABT-888, PARP-1 inhibitor ABT-888
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm
06/21
10/21
ACNS1721, NCT03581292: Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

Active, not recruiting
2
38
Canada, US, RoW
Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ, Veliparib, ABT 888, ABT-888, ABT888, PARP-1 inhibitor ABT-888
National Cancer Institute (NCI)
Anaplastic Astrocytoma, Glioblastoma, Malignant Glioma
03/23
10/26
NCT03289910: Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia

Active, not recruiting
2
25
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Topotecan, Hycamptamine, Topotecan Lactone, Topotecan Hydrochloride, Evotopin, Hycamtin, Nogitecan Hydrochloride, Potactasol, SKF S 104864 A, SKF S-104864-A, SKF S104864A, Topotec, Topotecan HCl, topotecan hydrochloride (oral), Veliparib, ABT 888, ABT-888, ABT888, PARP-1 inhibitor ABT-888
National Cancer Institute (NCI)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Essential Thrombocythemia, Myelodysplastic/Myeloproliferative Neoplasm, Myelofibrosis, Polycythemia Vera, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
05/23
12/25
NCT01149083: Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Completed
2
77
Canada, US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Veliparib, ABT 888, ABT-888, ABT888, PARP-1 inhibitor ABT-888
National Cancer Institute (NCI)
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Unresectable Breast Carcinoma
09/24
09/24
NCT01585805: Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Checkmark ASCO-GI 2015
Jan 2015 - Jan 2015: ASCO-GI 2015
Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Checkmark ASCO-2013
More
Active, not recruiting
2
88
Canada, US, RoW
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Gemcitabine Hydrochloride, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Veliparib, ABT 888, ABT-888, ABT888, PARP-1 inhibitor ABT-888
National Cancer Institute (NCI)
Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
12/24
03/26
SWOG S1416, NCT02595905: Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

Checkmark In combination with cisplatin in BRCA-like TNBC at ASCO 2020
Jun 2020 - Jun 2020: In combination with cisplatin in BRCA-like TNBC at ASCO 2020
Completed
2
344
US
Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Laboratory Biomarker Analysis, Placebo Administration, Veliparib, ABT 888, ABT-888, ABT888, PARP-1 inhibitor ABT-888
National Cancer Institute (NCI)
Metastatic BRCA Hereditary Breast Carcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Triple-Negative Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
01/25
03/25
I-SPY 2, NCT01042379: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Hourglass Jul 2025 - Dec 2025 : Top-line P1b data from ALX148 and Enhertu combo for breast cancer
Hourglass Dec 2025 - Dec 2025 : Data of vepdegestrant mono or in combo with letrozole or abema for neoadj stage 2/3 HR+ HER2- BC
Hourglass Jan 2023 - Dec 2023 : From P2 I-SPY 2 trial for invasive breast cancer
Checkmark Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
More
Recruiting
2
5000
US
Standard Therapy, Paclitaxel (Taxol); Doxorubicin (Adriamycin), AMG 386 with or without Trastuzumab, AMG 386 (Trebananib); (Trastuzumab) Herceptin, AMG 479 (Ganitumab) plus Metformin, Ganitumab, MK-2206 with or without Trastuzumab, (Trastuzumab) Herceptin, AMG 386 and Trastuzumab, AMG 386 (Trebananib); Trastuzumab (Herceptin), T-DM1 and Pertuzumab, T-DM1 (Trastuzumab emtansine); Pertuzumab (Perjeta), Pertuzumab and Trastuzumab, Pertuzumab (Perjeta); Trastuzumab (Herceptin), Ganetespib, ABT-888, Veliparib, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, Trilaciclib (G1T28); Pertuzumab (Perjeta); Trastuzumab (Herceptin), SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar (Oraxol); Dostarlimab (TSR-042); Trastuzumab (Herceptin), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, SAR439859, Amcenestrant + Abemaciclib, Amcenestrant (SAR439859), Abemaciclib (Verzenio), Amcenestrant + Letrozole, Amcenestrant (SAR439859), Letrozole (Femara), ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, VOYAGER V1™, VSV-IFNβ-NIS, Datopotamab deruxtecan, Dato-DXd, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel, GSK 5733584, GSK 5733584 + Dostarlimab
QuantumLeap Healthcare Collaborative
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
12/30
12/31
NCT01326702: Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors

Completed
1b/2a
43
US
Bendamustine Hydrochloride, Bendamustin Hydrochloride, Cytostasan Hydrochloride, Levact, Ribomustin, SyB L-0501, Treanda, Pharmacological Study, Rituximab, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab Biosimilar BI 695500, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, RTXM83, Veliparib, ABT-888, PARP-1 inhibitor ABT-888
National Cancer Institute (NCI)
Adult B Acute Lymphoblastic Leukemia, Adult Nasal Type Extranodal NK/T-Cell Lymphoma, Adult Solid Neoplasm, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma, Chronic Lymphocytic Leukemia, Cutaneous B-Cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Hepatosplenic T-Cell Lymphoma, Intraocular Lymphoma, Lymphomatous Involvement of Non-Cutaneous Extranodal Site, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Nodal Marginal Zone Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides and Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Plasma Cell Myeloma, Small Intestinal Lymphoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Waldenstrom Macroglobulinemia
04/15
04/15
NCT00770471: ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Completed
1/2
24
US
temozolomide, veliparib, DNA methylation analysis, gene expression analysis, mutation analysis, proteomic profiling, high performance liquid chromatography, immunoenzyme technique, laboratory biomarker analysis, mass spectrometry, pharmacogenomic studies, pharmacological study, adjuvant therapy, radiation therapy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
03/12
03/12
NCT01026493: Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma

Completed
1/2
257
US
temozolomide 60 mg x 21 days, Temodar, Temodal, Temcad, temozolomide 75 mg x 21 days, ABT-888 20 mg x 21 days, Veliparib, ABT-888 40 mg x 21 days, Temozolomide 150 mg x 5 days, ABT-888 40 mg x 5 days
Radiation Therapy Oncology Group, National Cancer Institute (NCI), NRG Oncology
Brain and Central Nervous System Tumors
05/14
12/16
NCT01690598 / 2012-001661-32: Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status

Completed
1/2
22
Europe
Veliparib, Topotecan
Vejle Hospital, Abbott
Ovarian Cancer
01/15
02/15
Veli-BRCA, NCT01472783 / 2011-002099-18: Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Completed
1/2
49
Europe
Veliparib
Vejle Hospital, Abbott
Recurrent, Epithelial Ovarian Cancer
01/16
08/16
NCT01711541: Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer

Completed
1/2
24
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Hydroxyurea, Droxia, Hydrea, Hydroxycarbamide, Litalir, Onco-Carbide, Oncocarbide, Oxeron, SQ 1089, SQ-1089, Syrea, WR 83799, Laboratory Biomarker Analysis, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Placebo Administration, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Name of Radiation Therapy Course, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Veliparib, ABT-888, PARP-1 inhibitor ABT-888
National Cancer Institute (NCI)
Head and Neck Squamous Cell Carcinoma, Stage IVA Oropharyngeal Carcinoma AJCC v7, Stage IVB Oropharyngeal Carcinoma AJCC v7
02/18
05/23
NCT01514201: Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Completed
1/2
66
US
3-Dimensional Conformal Radiation Therapy, 3-dimensional radiation therapy, 3D CONFORMAL RADIATION THERAPY, 3D CRT, 3D-CRT, Conformal Therapy, Radiation Conformal Therapy, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Laboratory Biomarker Analysis, Pharmacological Study, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac, Veliparib, ABT-888, PARP-1 inhibitor ABT-888
National Cancer Institute (NCI)
Anaplastic Astrocytoma, Brain Stem Glioma, Childhood Mixed Glioma, Fibrillary Astrocytoma, Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma, Untreated Childhood Anaplastic Astrocytoma, Untreated Childhood Brain Stem Glioma, Untreated Childhood Fibrillary Astrocytoma, Untreated Childhood Giant Cell Glioblastoma, Untreated Childhood Glioblastoma, Untreated Childhood Gliosarcoma
03/18
03/18
NCT01012817: Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

Active, not recruiting
1/2
88
US
Laboratory Biomarker Analysis, Pharmacogenomic Study, PHARMACOGENOMIC, Pharmacological Study, Topotecan Hydrochloride, Evotopin, Hycamptamine, Hycamtin, Nogitecan Hydrochloride, Potactasol, SKF S 104864 A, SKF S-104864-A, SKF S104864A, Topotec, Topotecan HCl, topotecan hydrochloride (oral), Veliparib, ABT 888, ABT-888, ABT888, PARP-1 inhibitor ABT-888
National Cancer Institute (NCI)
Metastatic Malignant Solid Neoplasm, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Unresectable Solid Neoplasm
01/19
08/26
NCT02289690 / 2014-001764-35: Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer

Completed
1/2
221
Europe, Canada, US, RoW
Veliparib, ABT-888, Carboplatin, Etoposide, VP-16, Placebo
AbbVie
Small Cell Lung Cancer
04/19
04/19
NCT01386385: Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Active, not recruiting
1/2
53
US
3-Dimensional Conformal Radiation Therapy, 3-dimensional radiation therapy, 3D Conformal, 3D CONFORMAL RADIATION THERAPY, 3D CRT, 3D radiotherapy, 3D-CRT, Conformal Therapy, Radiation Conformal Therapy, Radiation, 3D Conformal, Three dimensional external beam radiation therapy (procedure), Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Laboratory Biomarker Analysis, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Placebo Administration, Veliparib, ABT 888, ABT-888, ABT888, PARP-1 inhibitor ABT-888
National Cancer Institute (NCI)
Lung Adenocarcinoma, Lung Adenocarcinoma, Mixed Subtype, Lung Large Cell Carcinoma, Lung Squamous Cell Carcinoma, Minimally Invasive Lung Adenocarcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
05/19
12/25
NCT02412371 / 2016-001659-32: A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC)

Terminated
1/2
48
US
Paclitaxel, Placebo for Veliparib, Carboplatin, Veliparib, ABT-888, Radiotherapy
AbbVie
Non-small Cell Lung Cancer Stage III
08/19
08/19
NCT01489865: ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer

Checkmark ASCO-GI 2013
Jan 2013 - Jan 2013: ASCO-GI 2013
Completed
1/2
64
US
ABT-888, veliparib, mFOLFOX-6, 5-Fluorouracil, Eloxatin
Georgetown University, Abbott
Metastatic Pancreatic Cancer
12/18
12/23
NCT03227016: Study in Patients With SCLC of Veliparib in Combination With Topotecan

Recruiting
1/2
30
Europe
veliparib, PARP inhibitor, Topotecan, Hycamtin
Central European Society for Anticancer Drug Research
Small Cell Lung Cancer SCLC
05/21
06/21

Download Options